Online inquiry

IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4273MR)

This product GTTS-WQ4273MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets LINGO1 gene. The antibody can be applied in Multiple sclerosis (MS) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001301186.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 84894
UniProt ID Q96FE5
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4273MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10532MR IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LY-3015014
GTTS-WQ1113MR IVTScrip™ mRNA-Anti-MAPT, ABBV-8E12(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABBV-8E12
GTTS-WQ7224MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
GTTS-WQ3162MR IVTScrip™ mRNA-Anti-O-antigen, AR-101(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AR-101
GTTS-WQ14794MR IVTScrip™ mRNA-Anti-CD40, SGN-40(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SGN-40
GTTS-WQ1175MR IVTScrip™ mRNA-Anti-TNF, ABP 501(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABP 501
GTTS-WQ3497MR IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BAN-2401
GTTS-WQ10219MR IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA LFB-R593
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW